Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merrimack Pharma

- PMLiVE

Pharma stocks rise after Donald Trump’s election win

But his exact healthcare and industry-focus remain uncertain

- PMLiVE

ApotheCom and Continuum Clinical expand strategic partnership

Team up to deliver real-world evidence-based integrated business solutions

- PMLiVE

Mylan facing US anticompetitive practice probe

Senate judiciary committee calls for fair competition review over EpiPen sales

- PMLiVE

Torrid times at Gilead lead to calls for a major M&A deal

HIV portfolio sales down almost 10% to $7.5bn despite strong $533m start for Epclusa

- PMLiVE

Takeda launches drug discovery biotech

Hopes Bridge Medicines will streamline the development process

- PMLiVE

Astellas buys Ganymed to boost immuno-oncology pipeline

Enters into €1.28bn deal for access to first-in-class gastric cancer blockbuster candidate

- PMLiVE

The Global Awards 2016 finalists announced

GSW Worldwide’s virtual reality epilepsy campaign among the 145 shortlisted entries

- PMLiVE

Opening up innovation

Paul-Peter Tak on GlaxoSmithKline’s R&D strategy and the pivotal role of immunology

Roche Basel Switzerland

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

- PMLiVE

J&J’s Caruso bullish on Remicade defence plans

Believes top-selling arthritis treatment will weather introduction of biosimilars in US market

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links